|
|
HVJ-Envelope |
|
Vaxjo ID |
485 |
|
Vaccine Adjuvant Name |
HVJ-Envelope |
|
Adjuvant VO ID |
VO_0005762
|
|
Description |
particulate antigen delivery system vaccine adjuvant that induces Th1-biased response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Japan |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
hemagluttinating virus of japan |
|
Preparation |
conversion of inactivated virus containing lipid envelope into a transfer vector |
|
Function |
Type: particulate antigen delivery system vaccine adjuvant. Induces Th1-biased immune profile. efficiently deliver DNAs, siRNAs, proteins and anti-cancer drugs into cells |
| References |
Kaneda et al., 2002: Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R, Kotani H. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Molecular therapy : the journal of the American Society of Gene Therapy. 2002; 6(2); 219-226. [PubMed: 12161188].
Okada et al., 2011: Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, Inoue Y, Matsumoto M, McMurray DN, De la Cruz EC, Tan EV, Abalos RM, Burgos JA, Saunderson P, Sakatani M. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Human vaccines. 2011; 7 Suppl; 60-67. [PubMed: 21546794].
|
|
